a16z Bio + Health #6: AI for Biologics With Mark DePristo and Peyton Greenside
On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guests Peyton Greenside and Mark DePristo of BigHat Biosciences. The conversation covers the growing role of artificial intelligence and machin…
Mark DePristo - designing antibodies with machine learning
We talk with Mark DePristo, founder and CEO of BigHat Biosciences, about building better antibody therapeutics using machine learning, overcoming the fear of failure, and the pros and cons of working in academia, for large companies like Google, and at a biotech start up.
The Bioinformatics CRO i…
E274 Mark DePristo, Founder & CEO at BigHat Biosciences
Today's guest is Mark DePristo, Founder & CEO at BigHat Biosciences in San Francisco, CA. Founded in 2019, BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Mark brings a wealth of experience to the company having previous…
Next Generation Sequencing & Autism
In this interview, Stan Lapidus and Mark DePristo from SynapDx explain how they are using next generation sequencing techniques to develop an RNA-based blood test that they hope will enable the earlier diagnosis of autism spectrum disorders in children.
Episode 9: Engineering Antibodies Through AI and Machine Learning to Accelerate the Design of More Effective Treatments for Patients
Decades ago, the terms “artificial intelligence” and “machine learning” were associated with rogue robots and nefarious computers in sci-fi books and movies. Today, these technologies are a part of our everyday lives and as innocuous as predictive text appearing in a messaging app, a robot on wheel…
From Code to Cures: Mark DePristo on the Zero-to-One Biotech Journey
Mark DePristo, former CEO of BigHat Biosciences, reveals why the best biotech innovation doesn't bolt on AI later but bakes it into research from day one. He shifts from scaling a clinical-stage antibody powerhouse to the nimble "zero-to-one" world of Ember AI Studios, where small teams leverage AI…
PODCAST-ZOEKMACHINE
U kunt onze website gebruiken om3,832,281podcasts en196,974,148afleveringen te zoeken op mensen, plaatsen of onderwerpen.
Investeren in kennis levert het beste rendement op, daarom luister ik naar podcasts.
‐ Benjamin "Llamacorn" Franklin
BEWERKEN
Bedankt voor uw hulp bij het up-to-date te houden van de podcast-database .
